The Role of the Endocannabinoid System in Psychiatric Disorders and Symptoms: a Pharmacological fMRI study
- Conditions
- addictionsmoking10037176
- Registration Number
- NL-OMON33616
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 48
•History of mild cannabis use for at least one year (<1/week and >= 4/year)
•Right-handedness, assessed with the Edinburgh Handedness Inventory
•Written informed consent of the subject
•Any clinical significant abnormality of any clinical laboratory test, including urinary drug screening
•Impaired physical health evaluated by medical history, physical (including neurological) examination and screening laboratory tests (see paragraph 8.3.1)
•Current diagnosis of abuse of drugs or alcohol (according to DSM-IV) except for tobacco
•Past but recent diagnosis of abuse of drugs or alcohol other than tobacco, i.e. within 12 months preceding study inclusion.
•Body Mass Index (B.M.I.) <18 kg/m2 or >28 kg/m2
•Any subject who received any investigational medication within 90 days prior to the start of the study or who is scheduled to receive an investigational drug
•The use of any medication within three weeks prior to the start of the study, except for paracetamol
•Claustrophobia
•Metal objects in or around the body (braces, pacemaker, metal fragments)
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p> The main study parameter is the blood-oxygen-level dependent (BOLD) signal. </p><br>
- Secondary Outcome Measures
Name Time Method <p>Behavioral measures and the concentration of plasma THC and its main<br /><br>metabolites will be obtained.</p><br>